Drug Information

Drug General Information
Drug ID
D00VMA
Former ID
DIB014504
Drug Name
Vatreptacog alfa (activated)
Synonyms
NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
Indication Bleeding [ICD9: 444, 453; ICD10:I74, I80-I82] Phase 3 [523543]
Company
Novo Nordisk A/S
Target and Pathway
Target(s) Coagulation factor VII Target Info Modulator [531867]
KEGG Pathway Complement and coagulation cascades
PANTHER Pathway Angiogenesis
Blood coagulation
PathWhiz Pathway Coagulation
Reactome BMAL1:CLOCK,NPAS2 activates circadian gene expression
Extrinsic Pathway of Fibrin Clot Formation
Gamma-carboxylation of protein precursors
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
Removal of aminoterminal propeptides from gamma-carboxylated proteins
WikiPathways Complement and Coagulation Cascades
PTM: gamma carboxylation, hypusine formation and arylsulfatase activation
Blood Clotting Cascade
Formation of Fibrin Clot (Clotting Cascade)
Circadian Clock
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 523543ClinicalTrials.gov (NCT01392547) Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors. U.S. National Institutes of Health.
Ref 531867Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.